BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Pharmacyclics, Inc. 

995 East Arques Avenue

Sunnyvale  California  94086  U.S.A.
Phone: 408-774-0330 Fax: 408-774-0340


SEARCH JOBS

View Clinical Trials from BioPharm Insight









 Company News
Pharmacyclics, Inc. (PCYC) Named 2014 Outstanding Company By BayBio (Bay Area Bioscience Association) 12/12/2014 8:23:38 AM
Pharmacyclics, Inc. (PCYC) Release: Longer Follow-Up IMBRUVICA (ibrutinib) Treatment Demonstrates Sustained Efficacy In Patients With Difficult-To-Treat Chronic Lymphocytic Leukemia (CLL) 12/9/2014 8:46:15 AM
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA (ibrutinib) Data Demonstrates Safety And Durability Of Response At Two-Year Follow-Up In Mantle Cell Lymphoma 12/9/2014 7:15:39 AM
Pharmacyclics, Inc. (PCYC) Release: Longer Follow-Up IMBRUVICA (ibrutinib) Treatment Demonstrates Sustained Efficacy In Patients With Difficult-To-Treat Chronic Lymphocytic Leukemia (CLL) 12/9/2014 7:12:54 AM
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA (ibrutinib) In Combination With Rituximab Data Shows Positive Benefit-Risk Profile In Hematologic Malignancy 12/9/2014 7:10:37 AM
Pharmacyclics, Inc. (PCYC) Announces Launch of informCLL Registry For Chronic Lymphocytic Leukemia (CLL) Patients 12/8/2014 9:29:57 AM
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA (ibrutinib) Data Suggests Promise In Multiple Myeloma 12/8/2014 7:38:13 AM
Pharmacyclics, Inc. (PCYC) Receives 2014 Society For Medicines Research Award For Drug Discovery For Ibrutinib (IMBRUVICA) 12/5/2014 1:03:03 PM
Pharmacyclics, Inc. (PCYC) Release: New IMBRUVICA (ibrutinib) Application Accepted By European Medicines Agency For Waldenstrom's Macroglobulinemia 12/1/2014 12:12:29 PM
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA® (ibrutinib) Data To Be Presented Across Multiple Histologies, Including In Eight Oral Presentations, At 2014 American Society of Hematology Annual Meeting 11/6/2014 9:15:21 AM
12345678910...